Preliminary Report: Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone

Metabolism: Clinical and Experimental

Volumn 48, Issue 1, 1999, Pages 1-2

  Matsumoto, Kazunari ^a,b   Miyake, Seibei ^a   Yano, Mayumi ^a   Ueki, Yukitaka ^a   Tominaga, Yuko ^a  

^a Sasebo Chuou Hospital   (Japan)

^b Sasebo Chuou Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; APOLIPOPROTEIN; CHROMAN DERIVATIVE; ISOPROTEIN; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; BLOOD; MIDDLE AGED;

ADULT; AGED; APOLIPOPROTEINS; APOPROTEIN(A); CHROMANS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PHENOTYPE; PROTEIN ISOFORMS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032608539     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90001-X     Document Type: Article

References (9)

1. Kumar S, Boulton AJM, Beck-Nielsen H, et al: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39:701-709, 1996
2. Petrie J, Small M, Connell J: "Glitazones," a prospect for non-insulin-dependent diabetes. Lancet 349:70-71, 1997
3. Matsumoto K, Miyake S, Yano M, et al: Increase of lipoprotein(a) with troglitazone. Lancet 350:1748-1749, 1997
4. Utermann G, Menzel HJ, Kraft HG, et al: Glycoprotein phenotypes. Inheritance and relation to Lp(a) lipoprotein concentration in plasma. J Clin Invest 80:458-465, 1987
5. Utermann G, Kraft HG, Menzel HJ, et al: Genetics of the quantitative Lp(a) trait. I. Relation of Lp(a) glycoprotein phenotypes to Lp(a) lipoprotein concentration in plasma. Hum Genet 78:41-46, 1988
6. Klausen C, Gerdes LU, Meinertz H, et al: Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolemia treated with bile acid sequestration. Eur J Clin Invest 23:240-245, 1993
7. Godsland IF, Stevenson JC: Insulin resistance: Syndrome or tendency? Lancet 346:100-103, 1995
8. Schaeffer EJ, Fava SL, Jenner JL, et al: Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271:999-1003, 1994
9. Chapman MJ, Huby T, Nigon F, et al: Lipoprotein(a): Implication in atherosclerosis. Atherosclerosis 110:S69-S75, 1994 (suppl)